In summary, the involvement of the S1P axis in such a range of pathogenic mechanisms related with the fibrogenic process makes it a desirable drug target, and strategies to reduce S1P signaling could be useful for treatment of patients with liver fibrosis. Here, MBTPS1 is linked to Hepatic fibrosis.